Clinical Trials Browser

INDUSTRY × capmatinib × Thoracic × Clear all

NCT04741789 2026-03-16

Managed Access Programs for INC280, Capmatinib

No longer available

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05488314 2026-03-13

METalmark

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03040973 2026-02-02

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03333343 2026-01-16

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Phase 1 Active not recruiting

EGFR-mutant Non-small Cell Lung Cancer

NCT05110196 2025-12-03

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

Phase 4 Completed

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04926831 2025-10-16

Geometry-N

Phase 2 Terminated

4 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT04575025 2025-09-15

Special Drug Use-results Surveillance of Tabrecta Tablets

Carcinoma, Non-Small-Cell Lung

NCT04677595 2025-06-24

GeoMETry-C

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT04427072 2025-05-16

GeoMETry-III

Phase 3 Terminated

22 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT05703516 2025-01-14

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04139317 2024-10-09

Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%

Phase 2 Terminated

76 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT04323436 2024-10-09

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

Phase 2 Terminated

31 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT02414139 2024-03-20

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Phase 2 Completed

373 enrolled 34 charts 3 FDA

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT02335944 2023-06-18

Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.

Phase 1/2 Terminated

177 enrolled 48 charts

Carcinoma, Non-Small-Cell Lung

NCT05675683 2023-01-09

Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib

Carcinoma, Non-Small-Cell Lung

NCT02323126 2022-02-28

Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer

Phase 2 Terminated

64 enrolled 28 charts

Carcinoma, Non-Small-Cell Lung

NCT03647488 2022-01-24

Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer

Phase 2 Completed

18 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung

NCT01610336 2021-04-08

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

Phase 2 Completed

161 enrolled 32 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01324479 2020-12-19

Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Glioblastoma

NCT04460729 2020-12-03

A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases

Phase 2 Withdrawn

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms